| 1 |
任成山，王关嵩，钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
|
| 2 |
Mei D, Tan WSD, Wong WSF. Pharmacological strategies to regain steroid sensitivity in severe asthma and COPD[J]. Curr Opin Pharmacol. 2019, 46: 73-81.
|
| 3 |
Meja KK, Rajendrasozhan S, Adenuga D, et al. Curcumin restores corticosteroid function in monocytes exposed to oxidants by maintaining HDAC2[J]. Am J Respir Cell Mol Biol, 2008, 39(3): 312-323.
|
| 4 |
Barnes PJ. Role of HDAC2 in the pathophysiology of COPD[J]. Annu Rev Physiol, 2009, 71: 451-464.
|
| 5 |
Gan LX, Li CY, Guo XJ, et al. Curcumin modulates the effect of histone modification on the expression of chemokines by type Ⅱ alveolar epithelial cells in a rat COPD model[J]. Int J Chron Obstruct Pulmon Dis, 2016, 11: 2765-2773.
|
| 6 |
甘丽杏，李成业，郭雪君. 慢性阻塞性肺疾病组蛋白去乙酰化酶与糖皮质激素抵抗[J]. 国际呼吸杂志，2010, 30(5): 283-285.
|
| 7 |
Tamimi A, Serdarevic D, Hanania NA. The effects of cigarette smoke on airway inflammation in asthma and COPD: therapeutic implications[J]. Respir Med, 2012, 106(3): 319-328.
|
| 8 |
Cheng SE, Luo SF, Jou MJ, et al. Cigarette smoke extract induces cytosolic phospholipase A2 expression via NADPH oxidase, MAPKs, AP-1, and NF-kappaB in human tracheal smooth muscle cells[J]. Free Radic Biol Med, 2009, 46(7): 948-960.
|
| 9 |
Adcock IM, Tsaprouni L, Bhavsar P, et al. Epigenetic regulation of airway inflammation[J]. Curr Opin Immunol, 2007, 19(6): 694-700.
|
| 10 |
Spagnolo P, Fabbri LM, Bush A. Long-term macrolide treatment for chronic respiratory disease[J]. Eur Respir J, 2013, 42(1): 239-251.
|
| 11 |
Sun XJ, Chen L, He ZY. PI3K/Akt-Nrf2 and anti-inflammation effect of macrolides in chronic obstructive pulmonary disease[J]. Current Drug Metabolism, 2019, 20, 301-304.
|
| 12 |
Cao YQ, Xuan SR, Wu YH. Effects of long-term macrolide therapy at low doses in stable COPD[J]. Int J Chron Obstruct Pulmon Dis, 2019, 14: 1289-1298.
|
| 13 |
Płusa Tadeusz. Azithromycin in the treatment of patients with exacerbation of chronic obstructive pulmonary disease[J]. Pol Merkur Lekarski, 2020, 48(283): 65-68.
|
| 14 |
Qiu SL, Zhong XN. Macrolides: a promising pharmacologic therapy for chronic obstructive pulmonary disease[J]. Ther Adv Respir Dis, 2017, 11(3): 147-155.
|
| 15 |
中华医学会呼吸病学慢性阻塞性肺疾病组. 慢性阻塞性肺疾病诊治指南(2007年修订版)[J]. 中华内科杂志，2007, 46(43): 254-261.
|
| 16 |
慢性阻塞性肺疾病急性加重(AECOPD)诊治专家组[J]. 国际呼吸杂志，2017, 37(14): 1041-1057.
|
| 17 |
Seemungal TA, Harper-owen R, Bhowmik A, et al. Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease[J]. Eur Respir J, 2000, 16(4): 677-683.
|
| 18 |
杨 阳，杨 雁. COPD缓解期患者血清PCT、IL-6、hs-CRP水平对急性加重的预测作用[J]. 广东医学，2017, 38(10): 1531-1533.
|
| 19 |
Barnes PJ. Glucocorticoid resistance in patients with asthma and chronic obstructive pulmonary disease [J]. Allergy Clin. Immunol, 2013, 3 (131): 636-645.
|
| 20 |
王 飞，贺 蓓. 组蛋白去乙酰化酶在慢性阻塞性肺疾病中的重要作用[J]. 国际呼吸杂志，2007, 27(13): 985-988.
|
| 21 |
Jiang ZL, Zhu L. Update on molecular mechanisms of corticosteroid resistance in chronic obstructive pulmonary disease[J]. Pulm Pharmacol Ther, 2016, 37: 1-8.
|
| 22 |
Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance[J]. Allergy Clin Immunol, 2006, 117: 522-543.
|
| 23 |
甘丽杏，熊维宁，郭雪君. 慢性阻塞性肺疾病炎症因子与组蛋白去乙酰化酶2表达的临床意义[J/CD]. 中华肺部疾病杂志，2021, 14(2): 195-198.
|
| 24 |
Hull EE, Montgomery MR, Leyva KJ. HDAC2 inhibitors as epigenetic regulators of the immune system: impacts on cancer therapy and inflammatory diseases[J]. Biomed Res Int, 2016, 2016: 8797206.
|
| 25 |
Joseph F, Patrick M, Andrew LD, et al. Oxidative and nitrosative stress and histone deacetylase-2 activity in exacerbations of chronic obstructive pulmonary disease[J]. Chest, 2016, 149(1): 62-73.
|
| 26 |
Parnham MJ, Erakovic HV, Giamarellosbourboulis EJ, et al. Azithromycin：mechanisms of action and their relevance for clinical applications[J]. Pharmacol Ther, 2014, 143(2): 225-245.
|
| 27 |
姚志刚，吴艳军，谭春婷，等. 阿奇霉素对香烟烟雾凝集物刺激的巨噬细胞炎症调控的机制研究[J]. 临床和实验医学杂志，2019, 18(23): 2465-2468.
|
| 28 |
Płusa T. Azithromycin in the treatment of patients with exacerbation of chronic obstructive pulmonary disease[J]. Pol Merkur Lekarski, 2020, 48(283): 65-68.
|